FRONTIER BIOTECHNOLOGIES Inc.

About Us

 
Home>About Us

Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health.  Our medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management.

Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), which is the counterpart of the Food and Drug Administration (FDA) in China, in May 2018 through a priority review process and has gained accelerated approval. Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States.

Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, our long-standing commitment to excellence is in everything we do throughthe entire development cycle from drug discovery, preclinical research to global clinical development.  This approach has enabled Frontier Biotech to emerge in the global market as a competitive player in the field of HIV long-acting treatment and immunotherapy.

Frontier Biotech was co-founded by three national distinguished experts, Dr. Dong Xie, Dr. Changjin Wang, and Dr. Rongjian Lu.  Hailed as one of the leading biotechnology companies in China in the field of innovative drug development for HIV and AIDS treatments, Frontier Biotech has been the recipient of numerous awards and accolades over the years.  Frontier Biotech has been named as the leading enterprise in the field of Anti-HIV Drug Development Special Project in the 13th “Five-Year Plan” New Drug Research and Development National Major Scientific and Technological Special Projects administered by State Ministry of Science and Technology.  Frontier Biotech is also named as one of the “Cultivation of Unicorn Enterprises” in the city of Nanjing, China. 

      Since its inception, Frontier Biotech has been deeply rooted in the field of long-acting peptides with strategic focus on cultivating differentiated product pipeline in order to serve the unmet medical needs of patients. Albuvirtide (ABT), with trade name as Aikening ®, is the core product of Frontier Biotech. It is a Category 1 new drug approved by NMPA in May 2018. 

                    Frontier Biotechnologies Inc.(Nanjing)


Frontier Biotech is an innovation-driven biopharmaceutical company. Through more than a decade of committed effort, Frontier Biotech has built an extraordinary team with international vision and deep expertise in new drug development and established a fully integrated state-of-the-art long-acting peptide new drug innovationplatformwith global intellectual properties. In addition to the launch of Aikening ®, a Category 1 product and the first long-acting HIV fusion inhibitor in the world, Frontier Biotech is advancing an array of clinical assets through our R&D pipeline.  This include smultiple programs reaching Phase 1 and 2 clinical trials in China and the United States.

Frontier Biotech is committed to continuous development, manufacturing, and commercialization of new medicines for serving the unmet medical needs of patients with serious diseases, domestically and internationally.

Frontier Biotech established its headquarter, R&D center and manufacturing facility in Nanjing, China. The existing solid-phase peptide synthesis and freeze-dry injectable product lines are GMP-certified by the National Medical Products Administration (NMPA) as part of the Aikening ®'s approval process.  In addition to building a strong core team for R&D, development, manufacturing and commercial operation, Frontier Biotech has been successfully leveraging strategic partnerships, collaboration and licensing relationships to shorten the development cycle and mitigate the development risk.  This allows Frontier Biotech to collaborate with manufacturers and marketers to bring innovative medicines to patients as quickly and safely as possible.

cs_07_1.jpg
cs_07_2.jpg

Develop Innovative Therapies to Better Human Lives